Nephros raises $5m in private money:
This article was originally published in Clinica
Executive Summary
New York-based renal disease therapy company Nephros has raised $5m following the sale of secured convertible notes to several investors. The proceeds will be used to fund product development and marketing and to provide working capital for commercialising its new water filtration technology. The company develops dialysis devices for patients suffering from end-stage renal disease; its latest water filtration device is designed to remove a broad range of bacteria, viral agents and toxic substances including - among others - salmonella, HIV, hepatitis and E coli.